Seraseq™ ctDNA Mutation Mix v2 WT
Ex Tax:
$1,412.00

To overcome the lack of patient-like reference materials for liquid biopsy, including drawbacks of existing methodologies such as sonication, SeraCare has developed a breakthrough technology that produces the most patient-like materials compared to native ctDNA. The Seraseq ctDNA Mutation Mix v2 is a highly multiplexed product for NGS-based ctDNA assays targeting cancer-relevant somatic mutations.

This specific ctDNA Mutation Mix v2 product has an allele frequency of 0% wild-type

  • Size distribution, library yield and complexity consistent with native ctDNA
  • Single sample with 40 clinically-relevant mutations across 28 genes, all at the same specified allele frequency
  • Offered as a purified DNA mixture for ease of use during assay development
  • Mutation targets precisely quantitated with digital PCR
  • Single well-characterized GM24385 human genomic DNA as background wild-type material
  • Manufactured in GMP-compliant and ISO 13485-certified facilities